Cell MedX Corp (CMXC) Initiates Discussions With Industry Specialists At Worrell Design

LAS VEGAS, NV--(Marketwired - August 04, 2015) - Cell MedX Corp. (OTCQB: CMXC) ("Cell MedX" or the "Company") a development stage company focused on the discovery, development and commercialization of therapeutic devices for patients with diseases such as diabetes, is pleased to advise of entry into discussions with noted multiple award-winning international product design firm, Worrell Design Inc. ("Worrell").

Founded in 1976, Worrell, headquartered in Minneapolis, Minnesota, is a product design, development and strategy firm that collaborates with leading medical device companies and entrepreneurs to improve lives globally through design. The company uses a range of 3D printing processes for rapid prototyping and manufacturing, along with injection molding processes to create a quick path to small batch production. Worrell has expertise in industrial design, engineering, human factors and FDA compliance, user experience, branding and packaging. For more information visit: www.worrell.com or www.worrell.com/newmagazine.

The Company recently commenced discussions with Mr. Serge Dubeau, VP of Design and Human Factors, and a Partner at Worrell, in order to initiate a review of the current Cell MedX concept as part of the Company's strategic planning. Subject to the results of the clinical trial program in California, Cell MedX management looks forward to identifying a number of key factors aimed at the eventual commercialization of its technology.

Mr. Dubeau notes, "I appreciate the opportunity to investigate the Cell MedX technology and would be delighted to assist their efforts in the rapidly growing diabetes treatment environment."

Cell MedX President and CEO Mr. Frank McEnulty comments, "We are pleased to have this opportunity to introduce our technology to Worrell and look forward to the possibility of benefiting from their experienced input at this juncture in our development cycle."

About Cell MedX Corp (OTCQB: CMXC)
Cell MedX Corp. is a development stage company focused on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes by developing technologies to help manage the illness and related complications. Through its wholly owned subsidiary, Avyonce Cosmedics Inc., Cell MedX Corp. is engaged in reselling and marketing of technology and equipment to the worldwide wellness industry as well as providing continuing education to health care professionals. For more information go to: www.cellmedx.com and visit us on Facebook.

On behalf of the Board of Directors of Cell MedX Corp.

Frank McEnulty
Chief Executive Officer and President.

Forward Looking Statements
This press release contains forward-looking statements. Forward-looking statements are subject to risks, uncertainties and assumptions and are identified by words such as "expects", "aims", "intends", "estimates", "projects", "anticipates", "believes", "could", "possibility" and other similar words. All statements addressing product performance, events, or developments that the Company expects or anticipates will occur in the future are forward-looking statements. Because the statements are forward-looking, they should be evaluated in light of important risk factors and uncertainties, some of which are described in the Company's Quarterly, Annual and Current Reports filed with the United States Securities and Exchange Commission (the "SEC"). Should one or more of these risks or uncertainties materialize, or should any of the Company's underlying assumptions prove correct, actual results may vary materially from those currently anticipated. In addition, undue reliance should not be placed on Company's forward-looking statements. In particular, the Company's e-balance Technology is still in development. The Company does not currently have any commercially marketable products based on the e-balance technology, and there is no assurance that the Company will be successful in its development efforts. Except as required by law, Cell MedX Corp. disclaims any obligation to update or publicly announce any revisions to any of the forward-looking statements contained in this press release. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. No stock exchange, securities commission or other regulatory body has reviewed nor accepts responsibility for the adequacy or accuracy of this release. Investors are advised to carefully review the reports and documents that Cell MedX Corp. files from time to time with the SEC, including its Annual, Quarterly and Current Reports.